The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

Babies treated with antibiotics in the first few weeks of their life are likely to show weaker immune responses to essential ...

Immunization programs save millions of lives every year by protecting against preventable diseases. The immune response to ...

Vaxcyte, Inc.'s positive phase 2 results for VAX-24 show promise in preventing invasive pneumococcal disease in infants. Click for PCVX's market opportunity.

VAX-24 has the potential to cover more serotypes than any infant pneumococcal vaccine on-market today and provide protection ... The Company is developing broad-spectrum conjugate and novel protein ...

the Company’s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20 ® (PCV20) in healthy infants. Based on ...

It develops broad-spectrum conjugate and novel protein vaccines to prevent ... Vaxcyte recently showed data suggesting that their pneumococcal vaccine is better than the current vaccines on the market ...

Capvaxive is a pneumococcal vaccine specifically designed to help protect adults ... for more cases of IPD in adults compared to PCV20 (pneumococcal 20-valent conjugate vaccine), as shown in these ...